Laferobion suppositories (candles) 150,000 IU 10 pcs.

Interferon alpha-2b recombinant has a pronounced antiviral, antiproliferative and immunomodulatory effect. The complex composition of Laferobion causes a number of new effects: in combination with tocopherol acetate and ascorbic acid, the antiviral activity of interferon alpha-2b recombinant increases by 10-14 times, its immunomodulatory effect on T- and B-lymphocytes is enhanced, the content of immunoglobulin E is normalized. Antibodies are not formed that neutralize the antiviral activity of interferon alpha-2b recombinant, even when using interferon for 2 years, the functioning of the endogenous system is normalized.

For children: in the complex therapy of acute respiratory viral infections (ARVI).

For children: in the complex therapy of acute respiratory viral infections, the recommended doses are:

Newborns and premature babies are prescribed 150,000 IU of the drug, 2 suppositories per day with a 12-hour interval. Treatment courses and breaks between courses are 5 days.

Premature newborns with a gestational age of less than 34 weeks should be prescribed the drug at 150,000 IU 3 times a day (every 8 hours) rectally. The course is 5 days.

Children aged 1 to 7 years – 500,000 IU 2 times a day.

Children aged 7-14 years – 1,000,000 IU 2 times a day for 5 days.

Hypersensitivity to the components of the drug; the presence of thyroid dysfunction in the patient; the presence of severe visceral disorders in patients with Kaposi’s sarcoma; severe cardiovascular diseases; psoriasis; severe liver and/or kidney dysfunction; epilepsy and other diseases of the central nervous system (including functional); chronic hepatitis against the background of progressive or decompensated cirrhosis of the liver; chronic hepatitis in patients receiving or recently receiving immunosuppressant therapy (except for a short course of corticosteroid therapy); autoimmune hepatitis or other autoimmune diseases in history. suppression of the myeloid germ of hematopoiesis.

All adverse reactions associated with the use of Laferobion are minor or moderate in severity and usually disappear after the end of treatment.

General disorders: when administering Laferobion, flu-like symptoms are possible: chills, fever, fatigue, lethargy, as well as headache, muscle and joint pain, increased sweating; rarely – vomiting, dizziness, hot flashes. Hypersensitivity reactions to the drug are possible.

Disorders of the hematopoietic system: with prolonged use, leukopenia, thrombocytopenia, anemia, and nosebleeds are possible.

Gastrointestinal tract and liver disorders: increased ALT and AST levels, LF, loss of appetite, liver dysfunction.

Endocrine disorders: thyroid dysfunction.

Central and peripheral nervous system disorders: with prolonged use, dizziness, sleep disturbances, confusion, anxiety and depressive states, increased excitability, drowsiness, ataxia, paresthesias are possible.

Cardiovascular system disorders: hypertension or hypotension are possible; rarely – tachycardia.

Skin and subcutaneous tissue disorders: allergic reactions, including rash (including herpetic), itching, redness.

Respiratory system disorders: cough.

Other: changes at the injection site, visual disturbances, renal dysfunction, electrolyte imbalance.

Treatment with Laferobion should be carried out under the supervision of a physician.

With prolonged use of the drug, a complete blood count, liver, kidney and thyroid function are monitored.

All patients are recommended to undergo a comprehensive peripheral blood test before starting and regularly during treatment, with mandatory qualitative and quantitative blood tests, as well as a biochemical blood test, including determination of electrolytes, calcium, liver enzymes and creatinine.

In all patients receiving the drug, it is recommended to carefully monitor the level of albumin in the blood plasma and prothrombin time.

The drug should be prescribed with caution in patients with a history of diseases such as diabetes mellitus with episodes of ketoacidosis and COPD, with blood clotting disorders (including pulmonary artery thrombophlebitis), and with severe myelosuppression.

When treating with the drug, it is necessary to ensure adequate hydration of the body; in case of fever, other causes of its occurrence should be excluded. It is recommended to use the drug against the background of antihistamine and antipyretic therapy.

The development of severe and moderate side effects requires dose adjustment, and in some cases, discontinuation of treatment.

Discontinue use of the drug in cases of: prolonged blood clotting time (in patients with chronic hepatitis), manifestations of pulmonary syndrome and radiological detection of infiltrate or impaired lung function, appearance or increase in severity of visual impairment, thyroid dysfunction (deviation from the norm of TSH level), decreased plasma albumin level and decreased prothrombin time.

If an immediate-type hypersensitivity reaction develops (urticaria, angioedema, bronchospasm, anaphylaxis), the drug should be immediately discontinued and appropriate measures taken.

The use of the drug after the expiration date is unacceptable. The drug is not subject to repeated quality control and extension of the shelf life after its expiration.

Use during pregnancy and breastfeeding. There are no data on the use of the drug during pregnancy and breastfeeding.

Children. Used in pediatric practice (see Method of administration).

Ability to influence the reaction rate when driving vehicles or working with other mechanisms. Some adverse effects from the CNS caused by the use of the drug may affect the ability of patients to drive vehicles and work with potentially dangerous mechanisms.

The drug should be used with caution simultaneously with opioid drugs, analgesics, hypnotics and sedatives (potentially causing a myelosuppressive effect).

When used simultaneously with drugs that are metabolized by oxidation (including xanthine derivatives – aminophylline and theophylline), the possibility of the effect of Laferobion on oxidative metabolic processes should be taken into account. The concentration of theophylline in the blood plasma should be monitored and, if necessary, the dosage regimen should be adjusted.

When using the drug in combination with chemotherapeutic drugs (cytarabine, doxorubicin, teniposide, cyclophosphamide), the risk of developing life-threatening toxic effects (their severity and duration) increases.

When used simultaneously with zidovudine, the risk of neutropenia increases.

To date, no cases of overdose with Laferobion have been described. However, as with any drug overdose, symptomatic therapy with monitoring of vital organ functions and careful observation of the patient’s condition is recommended.

In the original packaging to protect from light at a temperature of 2-8 °C.